SCHEMBL259367

SCHEMBL259367

CCOC(=O)c1oc2ncccc2c1NC(=O)c1ccccc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.73
ALDH1A1 P00352 6/20 0.73
SMN1; SMN2 Q16637 6/20 0.73
HPGD P15428 5/20 0.73
HSD17B10 Q99714 5/20 0.73
TSHR P16473 4/20 0.73
LMNA P02545 2/20 0.62
HTT P42858 1/20 0.62
MAPT P10636 8/20 0.56
TP53 P04637 6/20 0.56
NPSR1 Q6W5P4 2/20 0.50
THRB P10828 1/20 0.50
USP2 O75604 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259087 0.86 MAPT (0.57) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL259263 0.85 MAPT (0.53) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL14581998 0.84 HTT (0.57) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL259251 0.83 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL13102749 0.82 LMNA (0.51) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL13298498 0.80 HPGD (0.72) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL13318879 0.79 RAB9A (0.52) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL13318503 0.78 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL259261 0.77 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL259197 0.77 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KDM4E 2196/4885ALDH1A1 4428/4885SMN1; SMN2 4764/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KDM4E 2196/4885ALDH1A1 4428/4885SMN1; SMN2 4764/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KDM4E 2196/4885ALDH1A1 4428/4885SMN1; SMN2 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.